Register or Sign in to Save this opportunity, or Send an Inquiry.
HypoSpray ® Transdermal System
Transdermal Delivery Solutions Corp United States flag United States
Abstract ID:
The HypoSpray platform enables delivery of most pharmaceutical active ingredients in a pleasant, easy-to-use, spray-on product with nearly instant, direct absorption into the blood system and the result is early onset of relief.
Send an Inquiry
Broadly Enabling Technology: The HypoSpray® technology presents a paradigm shift in transdermal delivery of drugs, away from small dose – small molecule therapies and limited applications to drugs that require larger bio-available doses for efficacy. As the company’s technology can accommodate large molecules, management believes it has the potential to deliver up to 70% of the drugs listed in the Physician Pharmaceutical Guide. The platform enables delivery of most pharmaceutical active ingredients in a pleasant, easy-to-use product with nearly instant, direct, absorption into the blood system. By-passing directly into the blood compartment, the stomach and gut are protected from the effects of processing and metabolizing what is essentially a foreign substance, and virtually eliminating stomach discomfort and concerns with taking medicine with meals or avoiding certain beverages or foods.  The smaller dose of drug used in the HypoSpray® formula renders any drug normally taken by mouth safer by reducing toxicity, side effects and  the potential for drug interactions.  Technological Integration is Proven: The flexible, broadly enabling nature of the platform technology has been proven safe and effective in several studies, which have been published in peer-reviewed journals, and have demonstrated superiority of HypoSpray® systems over the market leaders, thereby minimizing the risk of technological change, while maximizing the product’s attractiveness over existing market competition.

Type of Business Relationship Sought
As the Company's products address large markets requiring deep distribution capabilities, TDSC's commercialization strategy is to enter into join ventures with corporate partners who have the capability to gain meaningful market share and product revenues. The Company intends to use the strength and skills of its partners through their established market knowledge in brand positioning, distribution, marketing, sales, and scientific resources, so that the Company can maximize its return from the delivery mechanism for these approved drugs, broadening the diversity of its revenue base.

A typical transaction would include fees for accessing and securing a license for a particular API or category, milestone payments, and royalties on sales. Co-development utilizing the company’s cGMP, regulatory compliance and clinical capabilities and relationships are negotiable.

While the company has licensed some applications to development partnerships, the Company retains control of out licensed opportunities in all therapeutic categories. The company will evaluate potential opportunities for collaborations on new chemical entities (NCE’s) on a case-by-case basis with a close regard to obligations in particular therapeutic categories either established or pending.
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833